Development of the magnetic bioaffinity carrier for the anti-amyloid beta 1–42 antibodies detection

Abstract

In this paper, the development of a new affinity carrier was the key point for the anti-amyloid ß 1–42 antibodies detection in human serum, as the potential marker of the Alzheimer’s disease. Magnetic solid-phase preparation comprised the amyloid ß 1–42 peptide immobilization on the superparamagnetic carboxyl beads that had been modified by bisamino-polyethylene glycol spacer to gain terminal amine groups and subsequently analyzed by the zeta potential measurement. The following immobilization of the amyloid ß 1–42 peptide onto the modified superparamagnetic beads was performed by the carbodiimide chemistry. Nonspecific sorption of serum contaminants was prevented by using of bovine serum albumin. The developed magnetic carrier was analyzed by scanning electron microscopy. The amyloid ß 1–42 peptide bioaffinity carrier was applied for detection of natural anti-amyloid ß 1–42 antibodies in human serum. A comparison with spacer-free bioaffinity carrier has confirmed a divergent optical density values for control serum sample. The new bioaffinity carrier was applied to the detection of anti-amyloid ß 1–42 antibodies in control serum and in sera of patients with neurodegenerative disorders.